Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence

Giuseppe Bogina, Gianluigi Lunardi, Francesca Coati, Giuseppe Zamboni, Stefania Gori, Laura Bortesi, Marcella Marconi, Paola Agnese Cassandrini, Monica Turazza, Laura Cortesi, Elisabetta DeMatteis, Guido Ficarra, Toni Ibrahim, Patrizia Serra, Laura Medri, Sara Giraudi, Matteo Lambertini, Franca Carli, Jennifer Foglietta, Angelo Sidoni & 4 others Martina Nunzi, Corrado Ficorella, Maria Rosaria Diadema, Lucia Del Mastro

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims and background: The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence. Patients and methods: Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence. Results: Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgRpos), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgRneg), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgRloss). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95% CI 1.34-6.00) for PgRneg compared with PgRpos, and 2.93 (95% CI: 1.51-5.70) for PgRloss compared with PgRpos. Conclusions: PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.

Original languageEnglish
Pages (from-to)398-403
Number of pages6
JournalTumori
Volume101
Issue number4
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Recurrence
Neoplasm Metastasis
Neoplasms
Survival
Multicenter Studies
Multivariate Analysis
Retrospective Studies
Biomarkers

Keywords

  • Breast cancer
  • Locoregional recurrence
  • Metastasis
  • Progesterone receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. / Bogina, Giuseppe; Lunardi, Gianluigi; Coati, Francesca; Zamboni, Giuseppe; Gori, Stefania; Bortesi, Laura; Marconi, Marcella; Cassandrini, Paola Agnese; Turazza, Monica; Cortesi, Laura; DeMatteis, Elisabetta; Ficarra, Guido; Ibrahim, Toni; Serra, Patrizia; Medri, Laura; Giraudi, Sara; Lambertini, Matteo; Carli, Franca; Foglietta, Jennifer; Sidoni, Angelo; Nunzi, Martina; Ficorella, Corrado; Diadema, Maria Rosaria; Del Mastro, Lucia.

In: Tumori, Vol. 101, No. 4, 01.07.2015, p. 398-403.

Research output: Contribution to journalArticle

Bogina, G, Lunardi, G, Coati, F, Zamboni, G, Gori, S, Bortesi, L, Marconi, M, Cassandrini, PA, Turazza, M, Cortesi, L, DeMatteis, E, Ficarra, G, Ibrahim, T, Serra, P, Medri, L, Giraudi, S, Lambertini, M, Carli, F, Foglietta, J, Sidoni, A, Nunzi, M, Ficorella, C, Diadema, MR & Del Mastro, L 2015, 'Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence', Tumori, vol. 101, no. 4, pp. 398-403. https://doi.org/10.5301/tj.5000323
Bogina, Giuseppe ; Lunardi, Gianluigi ; Coati, Francesca ; Zamboni, Giuseppe ; Gori, Stefania ; Bortesi, Laura ; Marconi, Marcella ; Cassandrini, Paola Agnese ; Turazza, Monica ; Cortesi, Laura ; DeMatteis, Elisabetta ; Ficarra, Guido ; Ibrahim, Toni ; Serra, Patrizia ; Medri, Laura ; Giraudi, Sara ; Lambertini, Matteo ; Carli, Franca ; Foglietta, Jennifer ; Sidoni, Angelo ; Nunzi, Martina ; Ficorella, Corrado ; Diadema, Maria Rosaria ; Del Mastro, Lucia. / Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. In: Tumori. 2015 ; Vol. 101, No. 4. pp. 398-403.
@article{0cb7f53f3f28421ea853c45b46f2979c,
title = "Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence",
abstract = "Aims and background: The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence. Patients and methods: Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence. Results: Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgRpos), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgRneg), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgRloss). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95{\%} CI 1.34-6.00) for PgRneg compared with PgRpos, and 2.93 (95{\%} CI: 1.51-5.70) for PgRloss compared with PgRpos. Conclusions: PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.",
keywords = "Breast cancer, Locoregional recurrence, Metastasis, Progesterone receptor",
author = "Giuseppe Bogina and Gianluigi Lunardi and Francesca Coati and Giuseppe Zamboni and Stefania Gori and Laura Bortesi and Marcella Marconi and Cassandrini, {Paola Agnese} and Monica Turazza and Laura Cortesi and Elisabetta DeMatteis and Guido Ficarra and Toni Ibrahim and Patrizia Serra and Laura Medri and Sara Giraudi and Matteo Lambertini and Franca Carli and Jennifer Foglietta and Angelo Sidoni and Martina Nunzi and Corrado Ficorella and Diadema, {Maria Rosaria} and {Del Mastro}, Lucia",
year = "2015",
month = "7",
day = "1",
doi = "10.5301/tj.5000323",
language = "English",
volume = "101",
pages = "398--403",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence

AU - Bogina, Giuseppe

AU - Lunardi, Gianluigi

AU - Coati, Francesca

AU - Zamboni, Giuseppe

AU - Gori, Stefania

AU - Bortesi, Laura

AU - Marconi, Marcella

AU - Cassandrini, Paola Agnese

AU - Turazza, Monica

AU - Cortesi, Laura

AU - DeMatteis, Elisabetta

AU - Ficarra, Guido

AU - Ibrahim, Toni

AU - Serra, Patrizia

AU - Medri, Laura

AU - Giraudi, Sara

AU - Lambertini, Matteo

AU - Carli, Franca

AU - Foglietta, Jennifer

AU - Sidoni, Angelo

AU - Nunzi, Martina

AU - Ficorella, Corrado

AU - Diadema, Maria Rosaria

AU - Del Mastro, Lucia

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Aims and background: The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence. Patients and methods: Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence. Results: Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgRpos), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgRneg), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgRloss). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95% CI 1.34-6.00) for PgRneg compared with PgRpos, and 2.93 (95% CI: 1.51-5.70) for PgRloss compared with PgRpos. Conclusions: PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.

AB - Aims and background: The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence. Patients and methods: Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence. Results: Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgRpos), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgRneg), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgRloss). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95% CI 1.34-6.00) for PgRneg compared with PgRpos, and 2.93 (95% CI: 1.51-5.70) for PgRloss compared with PgRpos. Conclusions: PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.

KW - Breast cancer

KW - Locoregional recurrence

KW - Metastasis

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=84940919603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940919603&partnerID=8YFLogxK

U2 - 10.5301/tj.5000323

DO - 10.5301/tj.5000323

M3 - Article

VL - 101

SP - 398

EP - 403

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -